In the DAPA-HF trial, the SGLT2 inhibitor-mediated decrease in eGFR and increase in hematocrit are more likely independent of glycemia in people with and without diabetes (Lopaschuk and Verma 2020). This evidence concerns the gene SLC5A2 and diabetes mellitus.